Clinical therapeutic efficacy of mycophenolate mofetil in the treatment of SARDS in dogs—a prospective open‐label pilot study

Young, W. E.; Oh, Annie; Williams, Jonathan; Foster, Melanie L.; Miller, William; Lunn, Katharine F.; Mowat, Freya M.

doi:10.1111/vop.12545

Cited by 23 publications

(60 citation statements)

References 41 publications

(76 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…OCT is used in the live patient and allows near pan‐retinal microstructure data collection in a short period of time. To date, there are few reports describing the optical coherence tomography changes observed in SARDS dogs . These changes included small retinal detachments and retinal thinning.…”

Section: Introductionsupporting

confidence: 93%

Evaluation of retinal morphology of canine sudden acquired retinal degeneration syndrome using optical coherence tomography and fluorescein angiography

Osinchuk

Leis

Salpeter

et al. 2018

Veterinary Ophthalmology

View full text Add to dashboard Cite

show abstract

Section: Introductionsupporting

confidence: 93%

Evaluation of retinal morphology of canine sudden acquired retinal degeneration syndrome using optical coherence tomography and fluorescein angiography

Osinchuk

Leis

Salpeter

et al. 2018

Veterinary Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Recommended starting dosages for mycophenolate mofetil in dogs have varied from 10 to 20 mg/kg PO q12h, but gastrointestinal signs at the higher end of the dosage range often will necessitate dose reductions. Reported prevalence of diarrhea can be ≥20%, and may be delayed for 1‐2 weeks after starting treatment . Generally, starting dosages of 7‐10 mg/kg PO q12h (14‐20 mg/kg total daily dose) are associated with a much lower prevalence of diarrhea .…”

Section: Results and Recommendationsmentioning

confidence: 99%

“…In stable patients, therefore, a starting dosage of 8‐12 mg/kg q12h is recommended. If diarrhea occurs, it often is responsive to dose reduction …”

Section: Results and Recommendationsmentioning

confidence: 99%

See 1 more Smart Citation

ACVIM consensus statement on the treatment of immune‐mediated hemolytic anemia in dogs

Swann

Garden

Fellman

et al. 2019

Veterinary Internal Medicne

187

View full text Add to dashboard Cite

Immune‐mediated hemolytic anemia (IMHA) causes severe anemia in dogs and is associated with considerable morbidity and mortality. Treatment with various immunosuppressive and antithrombotic drugs has been described anecdotally and in previous studies, but little consensus exists among veterinarians as to the optimal regimen to employ and maintain after diagnosis of the disease. To address this inconsistency and provide evidence‐based guidelines for treatment of IMHA in dogs, we identified and extracted data from studies published in the veterinary literature. We developed a novel tool for evaluation of evidence quality, using it to assess study design, diagnostic criteria, explanation of treatment regimens, and validity of statistical methods. In combination with our clinical experience and comparable guidelines for humans afflicted with autoimmune hemolytic anemia, we used the conclusions of this process to make a set of clinical recommendations regarding treatment of IMHA in dogs, which we refined subsequently by conducting several iterations of Delphi review. Additionally, we considered emerging treatments for IMHA in dogs and highlighted areas deserving of future research. Comments were solicited from several professional bodies to maximize clinical applicability before the recommendations were submitted for publication. The resulting document is intended to provide clinical guidelines for management of IMHA in dogs. These guidelines should be implemented pragmatically, with consideration of animal, owner, and veterinary factors that may vary among cases.

show abstract

“…Three weeks into the experiment using 1% pirfenidone, dogs were sedated with dexmedetomidine (1.25 μg/kg) and butorphanol (0.1 mg/kg). The pupils were dilated with topical application of tropicamide and phenylephrine, and full‐field electroretinography was performed as previously described . Tissue samples were collected at 28 days as previously described for dogs receiving 0.5% pirfenidone.…”

Section: Methodsmentioning

confidence: 99%

Safety and efficacy of topically applied 0.5% and 1% pirfenidone in a canine model of subconjunctival fibrosis

Westermeyer

Salmon

Baynes

et al. 2019

Veterinary Ophthalmology

Self Cite

View full text Add to dashboard Cite

Objective To evaluate tissue levels, safety, and efficacy of topical ophthalmic 0.5% and 1% pirfenidone in decreasing subconjunctival fibrosis. Animal studied Twelve normal beagle dogs Procedures A 5 × 1 mm diameter silicone disk was implanted subconjunctivally in one eye, and then dogs were treated with topical 0.5% pirfenidone (n = 9) in artificial tears or artificial tears alone (n = 3) for 28 days. To evaluate tissue drug levels, a single sample of tears, conjunctiva, and aqueous humor was collected 30 (n = 3), 90 (n = 3), and 180 min (n = 3) following administration of the last drop of pirfenidone, respectively. Fibrous capsule thickness and staining for Ki67 and fibroblast activation protein alpha (FAPα) were evaluated histologically. After a 2‐week washout, the experiment was repeated in the opposite eye and using 1% pirfenidone. Results Treatment with pirfenidone resulted in thinner fibrous capsules and decreased staining for FAPα with no adverse effects. The implant in one dog treated with pirfenidone extruded. There was no difference in tissue levels, capsular thickness, or staining for Ki67 or FAPα between dogs treated with 0.5% or 1% pirfenidone. Conclusions Pirfenidone may decrease fibrosis following glaucoma shunt surgery and can potentially be used indefinitely due to minimal side effects.

show abstract

Clinical therapeutic efficacy of mycophenolate mofetil in the treatment of SARDS in dogs—a prospective open‐label pilot study

Abstract: Mycophenolate mofetil as a sole agent has no measureable positive effect on physical health, vision, or retinal structure following a 6-week trial period. Further studies are needed to evaluate other treatment options for SARDS.

Cited by 23 publications

References 41 publications

Evaluation of retinal morphology of canine sudden acquired retinal degeneration syndrome using optical coherence tomography and fluorescein angiography

Evaluation of retinal morphology of canine sudden acquired retinal degeneration syndrome using optical coherence tomography and fluorescein angiography

ACVIM consensus statement on the treatment of immune‐mediated hemolytic anemia in dogs

Safety and efficacy of topically applied 0.5% and 1% pirfenidone in a canine model of subconjunctival fibrosis

Contact Info

Product

Resources

About